Merkel cell carcinoma recurrence risk estimation is improved by integrating factors beyond cancer stage: a multivariable model and web-based calculator.

Merkel cell carcinoma nomogram prognosis recurrence risk calculator

Journal

Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132

Informations de publication

Date de publication:
18 Nov 2023
Historique:
received: 30 04 2023
revised: 19 10 2023
accepted: 02 11 2023
medline: 21 11 2023
pubmed: 21 11 2023
entrez: 20 11 2023
Statut: aheadofprint

Résumé

Merkel cell carcinoma (MCC) recurs in 40% of patients. In addition to stage, factors known to affect recurrence risk include: sex, immunosuppression, unknown primary status, age, site of primary tumor, and time since diagnosis. Create a multivariable model and web-based calculator to predict MCC recurrence risk more accurately than stage alone. Data from 618 patients in a prospective cohort were used in a competing risk regression model to estimate recurrence risk using stage and other factors. In this multivariable model, the most impactful recurrence risk factors were: AJCC stage (p<0.001), immunosuppression (hazard ratio 2.05; p<0.001), male sex (1.59; p=0.003) and unknown primary (0.65; p=0.064). Compared to stage alone, the model improved prognostic accuracy (concordance index for two-year risk, 0.66 vs. 0.70; p<0.001), and modified estimated recurrence risk by up to 4-fold (18% for low-risk stage IIIA vs. 78% for high-risk IIIA over five years). Lack of an external data set for model validation. / Relevance: As demonstrated by this multivariable model, accurate recurrence risk prediction requires integration of factors beyond stage. An online calculator based on this model (at merkelcell.org/recur) integrates time since diagnosis and provides new data for optimizing surveillance for MCC patients.

Sections du résumé

BACKGROUND BACKGROUND
Merkel cell carcinoma (MCC) recurs in 40% of patients. In addition to stage, factors known to affect recurrence risk include: sex, immunosuppression, unknown primary status, age, site of primary tumor, and time since diagnosis.
PURPOSE OBJECTIVE
Create a multivariable model and web-based calculator to predict MCC recurrence risk more accurately than stage alone.
METHODS METHODS
Data from 618 patients in a prospective cohort were used in a competing risk regression model to estimate recurrence risk using stage and other factors.
RESULTS RESULTS
In this multivariable model, the most impactful recurrence risk factors were: AJCC stage (p<0.001), immunosuppression (hazard ratio 2.05; p<0.001), male sex (1.59; p=0.003) and unknown primary (0.65; p=0.064). Compared to stage alone, the model improved prognostic accuracy (concordance index for two-year risk, 0.66 vs. 0.70; p<0.001), and modified estimated recurrence risk by up to 4-fold (18% for low-risk stage IIIA vs. 78% for high-risk IIIA over five years).
LIMITATIONS CONCLUSIONS
Lack of an external data set for model validation.
CONCLUSION CONCLUSIONS
/ Relevance: As demonstrated by this multivariable model, accurate recurrence risk prediction requires integration of factors beyond stage. An online calculator based on this model (at merkelcell.org/recur) integrates time since diagnosis and provides new data for optimizing surveillance for MCC patients.

Identifiants

pubmed: 37984720
pii: S0190-9622(23)03220-6
doi: 10.1016/j.jaad.2023.11.020
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Aubriana M McEvoy (AM)

University of Washington, Department of Medicine, Division of Dermatology, Seattle, WA; Washington University in St. Louis, Department of Medicine, Division of Dermatology, St. Louis, MO.

Daniel S Hippe (DS)

Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA.

Kristina Lachance (K)

University of Washington, Department of Medicine, Division of Dermatology, Seattle, WA.

Song Park (S)

University of Washington, Department of Medicine, Division of Dermatology, Seattle, WA.

Kelsey Cahill (K)

University of Washington, Department of Medicine, Division of Dermatology, Seattle, WA.

Mary Redman (M)

Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA.

Ted Gooley (T)

Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA.

Michael W Kattan (MW)

Cleveland Clinic, Department of Quantitative Health Sciences, Cleveland, OH.

Paul Nghiem (P)

University of Washington, Department of Medicine, Division of Dermatology, Seattle, WA; Seattle Cancer Care Alliance, Seattle, WA.

Classifications MeSH